Release No 15/2010 Report on the Annual General Meeting of Affitech A/S Copenhagen and Oslo, April 30th, 2010 Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that the Annual General Meeting of the Company was held on Thursday April 29th in Copenhagen at 11:00 am. The matters decided at the Annual General Meeting were as follows. • The Board of Directors presented the Annual Report and this was adopted. • The Board of Directors' proposal that losses for the year be carried forward to the following year was approved. • None of the motions proposed by shareholder Olav Willadsen was approved. • Keith McCullagh, Arne Handeland and Pål Rødseth were re-elected to the Board of Directors. Ole Steen Andersen, Michel Pettigrew and Steinar Engelsen resigned and did not stand for re-election. Viktor Kharitonin, Aleksandr Shuster and Andrei Petrov were elected as new members of the Board of Directors. • Ernst & Young P/S was elected as the Company's state authorised public accountant. • The chairman of the meeting was authorised to file any resolutions required to be registered with the Commerce and Companies Agency. Following the General Meeting, the newly elected Board of Directors met and elected Aleksandr Shuster as the new Chairman and Keith McCullagh as Vice Chairman. For more information please contact: Affitech A/S: Dr Robert Burns, Chief Executive Officer, Tel # +45 50 99 76 42 Randi Krogsgaard, Corporate Communications Tel # +45 2048 8384 About Affitech Affitech AS is a publicly traded (Nasdaq OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.